The pharmaceutical community is excited with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 target that’s demonstrating significant promise in clinical trials for addressing obesity. Unlike some available weight loss solutions, retatrutide appears to provide a greater subst